Second-Line-Therapie des nichtkleinzelligen Lungenkarzinoms (NSCLC) – eine retrospektive Kostenanalyse

Autor:	O Pirk, A Gabriel, W Kotowa, U Gatzemeier, David F. Heigener
Rok vydání:	2008
Předmět:	Oncology medicine.medical_specialty Side effect business.industry medicine.disease respiratory tract diseases Clinical trial Pemetrexed Docetaxel Internal medicine Medicine In patient Erlotinib business Adverse effect Intensive care medicine Lung cancer neoplasms medicine.drug
Zdroj:	TumorDiagnostik & Therapie. 29:211-217
ISSN:	1439-1279 0722-219X
DOI:	10.1055/s-2008-1027527
Popis:	OBJECTIVES: Based on clinical trials the costs of second-line therapy with erlotinib (Tarceva®) versus docetaxel (Taxotere®) or pemetrexed (Alimta®) in patients with advanced non-small-cell lung cancer (NSCLC) were investigated. METHODS: Direct total costs per patient per quarter from the German statutory health insurances’-perspective were compared regarding the management of grade 3 / 4 adverse events (AEs). Resource utilisation data were obtained from clinical trials and/or were supplemented on the basis of the respective guidelines and prescribing information. Cost data were taken from published sources. Base year of the data was 2008. RESULTS: The total costs per patient per quarter considering the treatment of AEs amount to € 8227 with erlotinib being approximately € 2600 or € 8800 lower compared to docetaxel and pemetrexed (€10 814 and € 17 030, respectively). CONCLUSIONS: Due to its favourable side effect profile, erlotinib offers health economic advantages over second-line therapy of NSCLC with docetaxel and pemetrexed.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7c37ce91782f5076cc99638b68b29f76 https://doi.org/10.1055/s-2008-1027527 Zobrazit plný text záznamu